Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perinatal/Neonatal Case Presentation
  • Published:

Perinatal/Neonatal Case Presentation

U-500R and aspart insulin for the treatment of severe insulin resistance in pregnancy associated with pregestational diabetes

Abstract

Severe insulin resistance as a complication of diabetes in pregnancy is seen with increasing frequency. Treatment with large doses of insulin (>300 units perday) can be practically difficult. A woman with preexisting Type 2 diabetes mellitus and poor glycemic control presented in early pregnancy requiring over 1000 units of insulin daily. She was transitioned to subcutaneous U-500 (concentrated regular insulin) in combination with a rapid-acting insulin analog achieving good glycemic control and good maternal and fetal outcomes. U-500R insulin in conjunction with a rapid-acting insulin analog can be used safely in early pregnancy to improve glycemic control in severe insulin resistance due to pregestational diabetes.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Albrecht SS, Kuklina EV, Bansil P, Jamieson DJ, Whiteman MK, Kourtis AP et al. Diabetes trends among delivery hospitalizations in the US 1994-2004. Diabetes Care 2010; 33: 768–773.

    Article  Google Scholar 

  2. Cochran E, Musso C, Gorden P . The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28: 1240–1244.

    Article  CAS  Google Scholar 

  3. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009; 15: 71–79.

    Article  Google Scholar 

  4. de la Pena A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A et al. Pharmacokinetics and pharmacodynamics of high-dose human regular u-500 insulin versus human regular u-100 insulin in healthy obese subjects. Diabetes Care 2011; 34: 2496–2501.

    Article  CAS  Google Scholar 

  5. Davidson MB, Navar MD, Echeverry D, Duran P . U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 2010; 33: 281–283.

    Article  CAS  Google Scholar 

  6. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG . U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev 2007; 23: 265–268.

    Article  CAS  Google Scholar 

  7. Hatipoglu B, Soni S, Espinosa V . Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract 2006; 12: 542–544.

    Article  Google Scholar 

  8. Dolberg BK, Lenhard MJ . Successful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitus. Endocr Pract 2000; 6: 34–36.

    Article  CAS  Google Scholar 

  9. Wong VW, Pape AV . Extreme insulin resistance in a patient with pre-existing diabetes during pregnancy: role of U-500 insulin. Med J Aust 2009; 190: 650–651.

    PubMed  Google Scholar 

  10. Cochran E . U-500 Insulin: when more with less yields success. Diabetes Spectrum 2009; 22: 116–122.

    Article  Google Scholar 

  11. Segal AR, Brunner JE, Burch FT, Jackson JA . Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 2010; 67: 1526–1535.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Source of funding: This work was supported by internal departmental funds. No external grant or contract funding was used.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E J Murphy.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okeigwe, I., Yeaton-Massey, A., Kim, S. et al. U-500R and aspart insulin for the treatment of severe insulin resistance in pregnancy associated with pregestational diabetes. J Perinatol 33, 235–238 (2013). https://doi.org/10.1038/jp.2012.70

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2012.70

Keywords

This article is cited by

Search

Quick links